Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

AKT and p21 WAF1/CIP1 as potential genistein targets in BRCA1-mutant human breast cancer cell lines.

Anticancer research - 1 Jun 2010

Privat Maud, Aubel Corinne, Arnould Stephanie, Communal Yves, Ferrara Marc, Bignon Yves-Jean

Abstract excerpt

BRCA1 acts as a tumour suppressor and germ-line mutations within this gene are found in a large proportion of families with breast cancer. The aim of our study was to unravel the mechanism of action of genistein, the major soy phytoestrogen, in BRCA1-mutant human breast cancer cell lines. Four breast cancer cell lines were studied for their response to genistein, three of them harbouring different mutations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anticarcinogenic Agents
Share to Apoptosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Cell Line, Tumor

Share to Cyclin-Dependent Kinase Inhibitor p21

Share to Genes, BRCA1

Share to Genistein

Share to Proto-Oncogene Proteins c-akt

Source

Identifiers

PMID: 20651350

Genes

BRCA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

AKT and p21 WAF1/CIP1 as potential genistein targets in BRCA1-mutant human breast cancer cell lines.PMID 20651350Read ↗

Breast cancer cell response to genistein is conditioned by BRCA1 mutations.Semantic proximity Read ↗

BRCA1 modulates malignant cell behavior, the expression of survivin and chemosensitivity in human breast cancer cellsSemantic proximity Read ↗

Genistein inhibits Brca1 mutant tumor growth through activation of DNA damage checkpoints, cell cycle arrest, and mitotic catastrophe.Semantic proximity Read ↗

p53, BRCA1 and breast Cancer chemoresistance.Semantic proximity Read ↗

Inhibition of constitutively activated phosphoinositide 3-kinase/AKT pathway enhances antitumor activity of chemotherapeutic agents in breast cancer susceptibility gene 1-defective breast cancer cells.Semantic proximity Read ↗

Targeting the Akt/mTOR pathway in Brca1-deficient cancers.Semantic proximity Read ↗

Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriersSemantic proximity Read ↗

BRCA1-mediated G2/M cell cycle arrest requires ERK1/2 kinase activation.Semantic proximity Read ↗

The effect of loss of Brca1 on the sensitivity to anticancer agents in p53-deficient cellsSemantic proximity Read ↗

Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.Semantic proximity Read ↗

BRCA1 shifts p53-mediated cellular outcomes towards irreversible growth arrest.Semantic proximity Read ↗

Sensitivity of TP53-Mutated Cancer Cells to the Phytoestrogen Genistein Is Associated With Direct Inhibition of Plk1 Activity.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.